Deutsche Bank Ag\ Praxis Precision Medicines, Inc. Transaction History

Deutsche Bank Ag\

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.83 - $1.18 $19,902 - $28,295	-23,979 Reduced 91.27%	2,294 $2,000
Q1 2023 May 15, 2023	BUY	$0.8 - $4.98 $9,847 - $61,298	12,309 Added 88.15%	26,273 $21,000
Q4 2022 Feb 13, 2023	BUY	$1.88 - $36.45 $475 - $9,221	253 Added 1.85%	13,964 $33,000
Q3 2022 Nov 14, 2022	SELL	$2.5 - $37.95 $13,087 - $198,668	-5,235 Reduced 27.63%	13,711 $31,000
Q2 2022 Aug 11, 2022	SELL	$1.75 - $11.34 $4,019 - $26,047	-2,297 Reduced 10.81%	18,946 $47,000
Q1 2022 May 13, 2022	SELL	$10.21 - $20.29 $19,786 - $39,322	-1,938 Reduced 8.36%	21,243 $217,000
Q4 2021 Feb 11, 2022	BUY	$16.76 - $22.99 $34,492 - $47,313	2,058 Added 9.74%	23,181 $457,000
Q3 2021 Nov 04, 2021	BUY	$13.15 - $22.56 $54,690 - $93,827	4,159 Added 24.52%	21,123 $391,000
Q2 2021 Aug 11, 2021	BUY	$18.28 - $33.05 $172,873 - $312,553	9,457 Added 125.98%	16,964 $310,000
Q1 2021 May 13, 2021	SELL	$29.34 - $60.2 $19,540 - $40,093	-666 Reduced 8.15%	7,507 $245,000
Q4 2020 Feb 16, 2021	BUY	$27.25 - $55.82 $222,714 - $456,216	8,173 New	8,173 $450,000

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.54B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.